LOGO
LOGO

Elicio Presents Encouraging Efficacy Data AMPLIFY-201 Trial

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Elicio Therapeutics (ELTX) presented updated results from its phase 1 AMPLIFY-201 clinical trial of ELI-002 in individuals with mutant KRAS-driven colorectal or pancreatic cancer.

ELI-002 is designed as an off-the-shelf vaccine to target KRAS mutations, a driver in approximately 25% of all solid tumors.

The AMPLIFY-201 trial involved 20 patients with pancreatic ductal adenocarcinoma and five with colorectal cancer.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.